slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 65,341-65,370
Pages 2,605
Rows per page 30
Component
65,341-65,370 of 78,138
17
Uses a before-after framing to demonstrate balance sheet optimization and future resilience.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · DevelopmentLoop · Before After1 hit
20
KeyCorp | Results Presentation Deck | 30 slidesKeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · DevelopmentLoop · Before After1 hit
21
KeyCorp | Results Presentation Deck | 30 slidesKeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · DevelopmentLoop · Before After1 hit
22
The slide provides a breakdown of consumer loans by type and a trend chart for wealth management assets.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · DevelopmentLoop · Before After1 hit
25
Includes a stacked bar chart showing hedge actions by quarter and a table summarizing the hedge portfolio.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · DevelopmentLoop · Before After1 hit
05
Includes a world map background with regional revenue/employee distribution bar and list of office locations.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
22
Lazard | Investor Presentation Deck | 46 slidesLazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations 1 hit
25
The slide uses a process diagram to show the evolution of funding stages and a pie chart to represent the $11T AUM market.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations 1 hit
31
The chart shows a debt maturity ladder alongside cash and undrawn revolver availability.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
32
The chart uses a stacked bar format for capital returns and a separate line/box format for net income.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
04
The chart shows a stacked bar representation of U.S. vs EU sales growth over time.Legend Biotech | Investor Presentation Deck | 14 slides · Legend Biotech
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The chart highlights Carvykti's superior growth curve in its first six quarters compared to the peer set.Legend Biotech | Investor Presentation Deck | 14 slides · Legend Biotech
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
13
The slide uses a three-part narrative structure: investment, acquisitions, and financial outcome.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · ProductLoop · Cost Of Inaction1 hit
20
Includes detailed footnotes explaining the valuation and ownership calculations.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · FinancialsLoop · Why Now1 hit
22
The chart uses a waterfall structure to bridge gross debt to allocated net debt for Lionsgate Studios.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · FinancialsLoop · Why Now1 hit
16
The chart illustrates the bridge between 2022 and 2023 revenue figures.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Satisfaction1 hit
18
The chart uses a grouped bar structure for each region, showing Q1-Q4 and the full-year 2023 average.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Satisfaction1 hit
20
The chart displays quarterly performance (Q1-Q4) and full-year 2023 for six business segments.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Satisfaction1 hit
23
The chart illustrates a bridge from 21,055 M€ in 2022 to 22,802 M€ in 2023.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · ActionLoop · Before After1 hit
25
The slide uses a stacked bar chart to represent the balance sheet structure.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
28
The 2023 dividend is subject to approval at the Annual General Meeting.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
10
The chart demonstrates tumor volume reduction over time, highlighting the efficacy of the THIO + Atezo combination.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
16
The chart tracks individual patient timelines, including disease progression, partial responses, and study outcomes.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
20
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
26
The slide contrasts the massive combined market of established CPIs ($42B) with the smaller market share of Libtayo ($0.5B) to frame the opportunity for partnership/growth.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
31
The slide shows a biological mechanism of action (MOA) validation using TIFs as a biomarker.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The chart shows dose-response curves where LNC formulations consistently outperform Taxol.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
22
The slide uses a timeline diagram to explain the experimental design and a line chart to show tumor volume reduction over time.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The study is an ex-vivo human whole blood study using 80 ug/mL LNC and 512 ng/mL Cy5-labeled siRNA cargo.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
06
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit